There is one drug approved in the United States for treating syphilis during pregnancy, one company makes it, and there is no substitute that prevents a baby from being born infected. That combination is now a supply problem that runs into late 2027.
King Pharmaceuticals, a Pfizer subsidiary, has extended the next delivery of 1.2 million-unit and 2.4 million-unit prefilled syringes of Bicillin L-A to October 2026, and pushed the anticipated recovery date to the fourth quarter of 2027, according to CDC. State health departments have been issuing rolling provider advisories ever since, including a Minnesota Department of Health update in July and a Maine CDC advisory in June.
